Jingyuan Luo

Jing’s practice is primarily focused on patent and trade secret litigation. Her experience covers a broad range of technologies including small molecules (salts, polymorphs, formulations, and process patents) and biologic drugs, medical devices, diagnostics, software, and semiconductors.  She has worked on Hatch Waxman (ANDA) litigation as well as Biologics Price Competition and Innovation Act (BPCIA) cases defending multi-billion-dollar diabetes and cancer drugs from generic/biosimilar challenges. Her clients have ranged from big pharmaceutical companies, to biotechnology companies, to pre-IPO startups, which uniquely positions her to counsel companies at all stages on portfolio strategy. Jing’s extensive background in biosciences, including years of laboratory research experience, serves her clients well in  high-stakes matters before the Patent Trial and Appeal Board, U.S. District Courts, and Federal Circuit. Recently, Jing helped defend the validity of all challenged claims in a salt/polymorph patent in an IPR and was instrumental in developing parallel district court cases for a blockbuster diabetes drug.

Prior to joining Orrick, Jing served as a judicial law clerk for Judge Raymond T. Chen at the U.S. Court of Appeals for the Federal Circuit and was an associate at a Vault 100 litigation boutique in Washington, D.C. Before law school, Jing was a Marshall Scholar, and she pursued dual graduate degrees in biosciences and policy studies while conducting public policy research in the U.K. and the United States.